Stuart Cobb

CIK: 0001994301

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NGNE

Neurogene Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
4K shares at avg. $20.41$81K
NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
2.7K shares at avg. $21.34$57K
NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
148 shares at avg. $22.08$3K
NGNE
Neurogene Inc.
Feb 20, 2026
Award(A)
Direct
16.5K shares-
NGNE
Neurogene Inc.
May 14, 2025
Sale(S)
Direct
6.8K shares at avg. $15.15$103K
NGNE
Neurogene Inc.
Mar 26, 2025
Award(A)
Direct
7.2K shares-

		Type	Shares	Price		Ownership
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	3,991	$20.41	$81,456	Direct
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	2,658	$21.34	$56,722	Direct
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	148	$22.08	$3,268	Direct
Feb 20, 2026	NGNE Neurogene Inc.	Award(A)	16,500	-	$0	Direct
May 14, 2025	NGNE Neurogene Inc.	Sale(S)	6,797	$15.15	$103,003	Direct
Mar 26, 2025	NGNE Neurogene Inc.	Award(A)	7,200	-	-	Direct

1-6 of 6 transactions

About Cobb Stuart

Cobb Stuart (SEC CIK 0001994301) files insider reports with the SEC as Chief Scientific Officer of Neurogene Inc. (NGNE).

Signal8 holds 4 ownership filings by Cobb Stuart, all Form 4s, filed between Mar 28, 2025 and Mar 17, 2026. Those filings report 6 transactions, from Mar 26, 2025 to Mar 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cobb Stuart's filings is in NEW YORK, NY.

Recent filings by Cobb Stuart

Mar 13, 2026: Open-market sales of NGNE shares (3 lines, Form 4, code S).
Feb 20, 2026: Grant or award of NGNE shares (Form 4, code A).
May 14, 2025: Open-market sale of NGNE shares (Form 4, code S).
Mar 26, 2025: Grant or award of NGNE shares (Form 4, code A).

Other insiders filing for Neurogene Inc. (NGNE)

McMinn Rachel, Chief Executive Officer
Cvijic Christine Mikail, President and CFO
Woods Keith, Director
Shafer Christina, Chief Commercial Officer
Jordan Julie, Chief Medical Officer
PALEKAR ROHAN, Director

How to read Form 4 transaction codes